289 related articles for article (PubMed ID: 27738759)
21. Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma†.
Ito M; Miyata Y; Yoshiya T; Tsutani Y; Mimura T; Murakami S; Ito H; Nakayama H; Okada M
Eur J Cardiothorac Surg; 2017 Feb; 51(2):218-222. PubMed ID: 28186287
[TBL] [Abstract][Full Text] [Related]
22. Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients.
Pan Y; Yuan C; Cheng C; Zhang Y; Ma Y; Zheng D; Zheng S; Li Y; Jin Y; Sun Y; Chen H
Int J Cancer; 2019 Jan; 144(2):290-296. PubMed ID: 30230541
[TBL] [Abstract][Full Text] [Related]
23. [Relationship between EGFR Mutations and Pathological Classification and
Specimen of Lung Adenocarcinoma].
Kang L; Zheng J; Zhu X
Zhongguo Fei Ai Za Zhi; 2017 Jun; 20(6):382-388. PubMed ID: 28641695
[TBL] [Abstract][Full Text] [Related]
24. Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations.
Wang H; Schabath MB; Liu Y; Han Y; Li Q; Gillies RJ; Ye Z
Eur J Radiol; 2016 Nov; 85(11):1934-1940. PubMed ID: 27776643
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes.
Lee HJ; Kim YT; Kang CH; Zhao B; Tan Y; Schwartz LH; Persigehl T; Jeon YK; Chung DH
Radiology; 2013 Jul; 268(1):254-64. PubMed ID: 23468578
[TBL] [Abstract][Full Text] [Related]
26. Clinical value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma.
Guo Z; Yi F; Yin W; Zhang Y; Li Q; Gu Y; Xiao Y; Cao B; Ma L; Liang L
Thorac Cancer; 2017 May; 8(3):159-169. PubMed ID: 28220630
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component.
Pan Y; Wang R; Ye T; Li C; Hu H; Yu Y; Zhang Y; Wang L; Luo X; Li H; Li Y; Shen L; Sun Y; Chen H
Chest; 2014 Mar; 145(3):473-479. PubMed ID: 24158231
[TBL] [Abstract][Full Text] [Related]
28. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
29. EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.
Lee JS; Kim HR; Lee CY; Shin M; Shim HS
Ann Surg Oncol; 2013 Sep; 20(9):3015-22. PubMed ID: 23525704
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
[TBL] [Abstract][Full Text] [Related]
31. Correlation of Histologic Subtypes and Molecular Alterations in Pulmonary Adenocarcinoma: Therapeutic and Prognostic Implications.
Kim J; Jang SJ; Choi CM; Ro JY
Adv Anat Pathol; 2016 Sep; 23(5):330-8. PubMed ID: 27403614
[TBL] [Abstract][Full Text] [Related]
32. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
33. Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells.
Pareja F; Crapanzano JP; Mansukhani MM; Bulman WA; Saqi A
Cancer Cytopathol; 2015 Mar; 123(3):162-70. PubMed ID: 25557162
[TBL] [Abstract][Full Text] [Related]
34. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations.
Tsuta K; Kawago M; Inoue E; Yoshida A; Takahashi F; Sakurai H; Watanabe SI; Takeuchi M; Furuta K; Asamura H; Tsuda H
Lung Cancer; 2013 Sep; 81(3):371-376. PubMed ID: 23891509
[TBL] [Abstract][Full Text] [Related]
35. The histopathology of BRAF-V600E-mutated lung adenocarcinoma.
Yousem SA; Nikiforova M; Nikiforov Y
Am J Surg Pathol; 2008 Sep; 32(9):1317-21. PubMed ID: 18636014
[TBL] [Abstract][Full Text] [Related]
36. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
[TBL] [Abstract][Full Text] [Related]
37. Primary lung adenocarcinoma with morule-like components: a unique histologic hallmark of aggressive behavior and EGFR mutation.
Tsuta K; Kawago M; Yoshida A; Sekine S; Asamura H; Furuta K; Kushima R
Lung Cancer; 2014 Jul; 85(1):12-8. PubMed ID: 24768118
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
39. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
Planck M; Isaksson S; Veerla S; Staaf J
Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
[TBL] [Abstract][Full Text] [Related]
40. Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis.
Onozato ML; Kovach AE; Yeap BY; Morales-Oyarvide V; Klepeis VE; Tammireddy S; Heist RS; Mark EJ; Dias-Santagata D; Iafrate AJ; Yagi Y; Mino-Kenudson M
Am J Surg Pathol; 2013 Feb; 37(2):287-94. PubMed ID: 23095504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]